TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02473796

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home based child care
Description: HBNC included treatment of neonatal sepsis with Gentamicin once daily (5 mg for 10 days for preterm babies with birth weight \<2000g; 7 mg for birth weight 2000-2500 gm or as per gentamicin chart for 7 days for normal term \& weight ) by intramuscular injection. Acute respiratory infection was treated with co-trimoxazole syrup BID (2.5 ml for age 1-2 months, 5 ml for age 2 months - 1 year, 7.5 ml for age 1 - 5 years). Diarrheal illness was treated with ORS, furoxone (5 ml 8 hourly for 3 days) and metronidazole syrup (5 ml 8 hourly for 7 days). Malaria was treated with Syrup chloroquine (for 1 month to 1 year- 5 ml first dose , 2.5 ml after 6 hours, 2.5 ml after 12 hours , 2.5 ml after 12 hours). Syrup paracetamol was given 2.5 to 5 ml 8 hourly depending upon the body weight.
Study: NCT00896961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EF5
Study: NCT02811666

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Assessment of sarcopenia by CT-Scan

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hand gauge
Study: NCT03021018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: * Pharmaceutical Form: Solution for infusion~* Concentration: 10 mg/ml~* Route of Administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: * Pharmaceutical Form: Solution for infusion~* Concentration: 10 mg/ml~* Route of Administration: intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: * Pharmaceutical Form: Solution for injection~* Route of Administration: intravenous
Study: NCT00132262

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief intervention based on motivational interviewing
Description: The intervention was an approximately 30 minute discussion about alcohol-related risk behaviors and motivation to change

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care including referral for treatment
Description: Standard hospital care provided the patient with information and referral for treatment as necessary.
Study: NCT04609722

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Solution-Focused Support Program
Description: All participants will be given a program of 4 sessions for 4 weeks. Each session is planned to last approximately 50 minutes.
Study: NCT01904344

Intervention type: DEVICE
Group type: OTHER
Intervention: Sensor testing and validation
Study: NCT04543760

Intervention type: OTHER
Group type: OTHER
Intervention: Prone position
Description: prone positioning in spontaneous ventilation

Intervention type: OTHER
Group type: OTHER
Intervention: Prone position
Description: prone positioning in spontaneous ventilation

Intervention type: OTHER
Group type: OTHER
Intervention: Supine position
Description: supine positiong in spontaneous ventilation

Intervention type: OTHER
Group type: OTHER
Intervention: Supine position
Description: supine positiong in spontaneous ventilation
Study: NCT02282189

Intervention type: DEVICE
Group type: OTHER
Intervention: Oscillating Positive Expiratory Pressure (Aerobika ®)
Description: The oPEP system combines positive expiratory pressure therapy and airway vibrations to help mobilize pulmonary secretions. oPEP therapy enforces a resistance to exhalation at the mouth, while the airway vibration technology transmits movements upstream during exhalation so that airway walls may become free from mucous. Subjects will take home the device and use four times daily during the active part of the study.
Study: NCT01635322

Intervention type: DEVICE
Intervention: Polyaxial posterior spinal fusion system
Description: posterior correction and fusion of the thoraco-lumbar or lumbar spine
Study: NCT03633474

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N. lactamica
Description: Stocks of N. lactamica (strain Y92-1009, sequence type 3493, clonal complex 613) in Frantz medium containing 30% (v/v) glycerol have been previously prepared using the Good Manufacturing Practices pharmaceutical manufacturing facilities at Public Health England (Porton Down, United Kingdom).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PBS only
Description: Sterile PBS only containing no bacteria
Study: NCT04525365

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pleural aspiration
Description: Pleural aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pleural aspiration
Description: Pleural aspiration
Study: NCT03961230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jueyin granules
Description: Put each bag of medicine in the same amount into the same container, pour about 50 ml of warm water, stir until the particles are basically dissolved, and then add appropriate amount of boiling water to dilute.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Jueyin Granules Placebo
Description: Put each bag of medicine in the same amount into the same container, pour about 50 ml of warm water, stir until the particles are basically dissolved, and then add appropriate amount of boiling water to dilute.
Study: NCT01900626

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epidural catheter
Description: epidural catheter with 0.3% ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epidural catheter
Description: epidural catheter with 0.3% ropivacaine
Study: NCT03611374

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Erector Spinae Plane Block (ESPB)
Description: Bilateral ESPBs will be placed after anesthesia induction in eligible and consented patients who are undergoing a sternotomy for congenital heart repair. Patients will receive a local anesthetic agent through each catheter prior to surgery start. If possible, levels of the local anesthetic will be measured during the case. After surgery, patients will be admitted to the CVICU and extubation will be managed by the CVICU team. The ESPB group will have an automatic, alternating side boluses of the local anesthetic started through their nerve block catheters. Levels of the local anesthetic will be measured at intervals.
Study: NCT00845715

Intervention type: OTHER
Group type: OTHER
Intervention: Early motion
Description: Early referral to physical therapy for range of motion (2 days post)

Intervention type: OTHER
Group type: OTHER
Intervention: Standard motion
Description: Standard referral to physical therapy for range of motion (4 weeks post)
Study: NCT01692717

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 10 mg
Study: NCT04555148

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC5131
Description: COVID19 Hyper-Immunoglobulin
Study: NCT01692717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide + Losartan
Description: 12.5 mg + 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide + Losartan
Description: 12.5 mg + 50 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide + Losartan
Description: 12.5 mg + 50 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide + Losartan + Atorvastatin
Description: 12.5 mg + 50 mg + 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide + Losartan + Atorvastatin
Description: 12.5 mg + 50 mg + 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide + Losartan + Atorvastatin
Description: 12.5 mg + 50 mg + 10 mg
Study: NCT02612298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arotinolol Hydrochloride
Description: Arotinolol Hydrochloride, oral, 5-15mg, bid for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol succinate sustained-release tablet
Description: Metoprolol succinate sustained-release tablet,oral, 23.75-71.25mg, qd for 12 weeks.
Study: NCT00989274

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccine Sanofi A(H1N1) 15 ug & trivalent
Description: Grup 1: day 0: Vaccine trivalent (A/Brisbane/59/2007 (H1N1)-like virus, A/Brisbane/10/2007 (H3N2)-like virus, and B/Brisbane/60/2008-like virus) Vaccine Sanofi A(H1N1) administrated 15 ug. (nonadjuvant); day 28 Vaccine Sanofi A(H1N1) administrated a 15 ug. (nonadjuvant);

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccine Sanofi (H1N1) 15 ug.nonadyuvante
Description: Grup 2: Day 0: Vaccine trivalent(A/Brisbane/59/2007 (H1N1)-like virus, A/Brisbane/10/2007 (H3N2)-like virus, y B/Brisbane/60/2008-like virus); Day 28 Vaccine Sanofi A(H1N1) administrated a 15 ug. (nonadjuvant); day 56; Vaccine Sanofi A(H1N1) administrated a 15 ug. (nonadjuvant)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccine Sanofi A(H1N1) 7.5 ug
Description: Grup 3: day 0: day 28 Vaccine Sanofi A(H1N1) administrated a 7.5 ug (non adjuvant); day 56; Vaccine Sanofi A(H1N1) administrated a 7.5 ug (nonadjuvant).
Study: NCT01519661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBM100
Description: Tobramycin inhalation powder was assigned as four capsules at 28mg dosage strength. It was inhaled b.i.d in the morning and in the evening via the T-326 Inhaler.
Study: NCT03918174

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dart splint orthosis
Description: The Dart Splint orthosis was fitted to the subjects in the research group on their first evaluation session. They received oral and written instructions regarding the donning and manner of exercise. Specifically, they were instructed to use the Dart splint orthosis at home. For each 10-minute exercise session, they were asked to perform 5 minutes of radial-extension under resistance and then 5 minutes ulnar-flexion under resistance. In addition, this group was required to fill in a chart at the end of each practice session (morning, noon and evening), throughout the intervention period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: The control group activated the wrist mostly in the sagittal plane. This group was instructed to perform at home active wrist motion similar to that practiced during the supervised therapy sessions. The prescribed instructions were similar to the exercises performed during the sessions. Specifically, they were instructed to exercise at home for 10-minute in each session, three times a day (morning, noon and evening), throughout the intervention period.
Study: NCT02584439

Intervention type: DRUG
Group type: OTHER
Intervention: ivabradine
Description: It is a cross over study with two arms : either ivabradine-placebo or placebo-ivabradine. The capsules containing the placebo or ivabradine are completely identical.

Intervention type: DRUG
Group type: OTHER
Intervention: ivabradine
Description: It is a cross over study with two arms : either ivabradine-placebo or placebo-ivabradine. The capsules containing the placebo or ivabradine are completely identical.

Intervention type: DRUG
Group type: OTHER
Intervention: lactose capsule (placebo)
Description: It is a cross over study with two arms : either ivabradine-placebo or placebo-ivabradine. The capsules containing the placebo or ivabradine are completely identical.

Intervention type: DRUG
Group type: OTHER
Intervention: lactose capsule (placebo)
Description: It is a cross over study with two arms : either ivabradine-placebo or placebo-ivabradine. The capsules containing the placebo or ivabradine are completely identical.
Study: NCT02959580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Butyrate
Description: topical use

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: extended excision
Description: Lesion extended excision with or without a random breast dermo-glandular flap (BDGF).
Study: NCT00723710

Intervention type: BIOLOGICAL
Intervention: Intron A (interferon alfa-2b; SCH 30500)
Description: The recommended regimen includes an induction treatment of 5 consecutive days per week for 4 weeks as a 20-minute intravenous (iv) infusion at a dose of 20 million international units per square meter (MIU/m\^2). The induction treatment should be followed by a maintenance treatment of 3 times per week for 48 weeks as a subcutaneous (sc) injection at a dose of 10 MIU/m\^2. Therapy should be administered for a total of one year unless the disease progresses or the treatment has lead to recurrent unmanageable serious adverse effects.
Study: NCT00509561

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Study: NCT01805765

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Qing'E pills
Description: composed of eucommia, psoralen, walnuts and garlic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Containing 2% of Qing'E pills
Study: NCT04376411

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow-cytometric assay
Description: 100 µl of blood sample was incubated for 20 minutes at 4 C in the dark. Following incubation, red blood cells lysis, washing and analysis a specific software.Forward and side scatter histogram was used to define the lymphocytes population.
Study: NCT04555148

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC5131
Description: COVID19 Hyper-Immunoglobulin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC5131
Description: COVID19 Hyper-Immunoglobulin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02763969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986202
Study: NCT00509561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study: NCT04187521

Intervention type: OTHER
Group type: OTHER
Intervention: Meal A
Description: A breakfast meal with a specific macronutrient proportions.
Study: NCT00896961

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study: NCT01891643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study: NCT02763969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2a recombinant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Study: NCT01466543

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zydena (Udenafil)
Description: Zydena (Udenafil) 100 mg, one time

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01599143

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teaching Mindfulness-based Stress Reduction strategies
Description: Daily meditation, Hatha yoga,and cognitive restructuring
Study: NCT00480948

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Infant formula feeding (InFat™)
Description: Infant formula with InFat™ oil (containing \~49% of C16:0 at sn-2 position), 24 wk

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Standard vegetable oil based infant formula
Study: NCT02643069

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Geriatric Program
Description: The investigators will implemented programs to detected and manage care for older patients in four settings: Emergency room, oncology department, surgery departments making major surgery and Cardiology. The core intervention will consist of the following elements: comprehensive geriatric assessment, coordination with primary ans social care, integrated and continued care, access to rehabilitation facilities, management of drug treatment avoiding polypharmacy and stressing adherence.
Study: NCT02150408

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET-CT
Study: NCT01173887

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VCAP/AMP/VECP(mLSG15)
Description: VCAP(Vincristine Sulfate, Cyclophosphamide Hydrate, Doxorubicin Hydrochloride, Prednisolone); AMP(Doxorubicin Hydrochloride, Ranimustine, Prednisolone); VECP(Vindesine Sulfate, Etoposide, Carboplatin, Prednisolone)
Study: NCT01891643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT01173887

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KW-0761
Description: VCAP/AMP/VECP(mLSG15) + KW-0761
Study: NCT04187521

Intervention type: OTHER
Group type: OTHER
Intervention: Meal B
Description: A breakfast meal with a specific macronutrient proportions.
Study: NCT05958693

Intervention type: DRUG
Intervention: Artemether-lumefantrine
Description: Artemether-lumefantrine will be administered for 3 days according to body weight (Days 0 and 8 hours after, 1 and 2). Dosage depending on body weight or age if weight cannot be determined.~Dosage: 1 tablet contains 20 mg artemether and 120 mg lumefantrine Dosage per weight: 1 tablet (5 to \<16kg); 2 tablets (15 to \<25kg); 3 tablets (25 to \<35kg), 4 tablets for \>35 kg) Dosage per age, if weight cannot be determined: 1 tablet (6 months old to 3 years old); 2 tablets (4 to 8 years old); 3 tablets (9-13 years old), 4 tablets (\>13 years old)
Study: NCT01891643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Study: NCT01725139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2126458
Description: GSK2126458 will be available as film coated tablet of dose strength 0.25 mg and 0.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2126458
Description: GSK2126458 will be available as film coated tablet of dose strength 0.25 mg and 0.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2126458
Description: GSK2126458 will be available as film coated tablet of dose strength 0.25 mg and 0.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2126458
Description: GSK2126458 will be available as film coated tablet of dose strength 0.25 mg and 0.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2126458
Description: GSK2126458 will be available as film coated tablet of dose strength 0.25 mg and 0.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2126458
Description: GSK2126458 will be available as film coated tablet of dose strength 0.25 mg and 0.5 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be available

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be available

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be available

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be available

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be available

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be available
Study: NCT03900780

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PGT-A
Description: ovarian stimulation, oocyte aspiration, embryo culture until the blastocyst stage (day 5/6), TE biopsy, vitrification of all embryos in the blastocyst stage, PGT-A by NGS and finally embryo transfer of genetically normal embryos in cumulative frozen-thawed embryo transfer cycles

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: ovarian stimulation, oocyte aspiration, embryo culture until the blastocyst stage, fresh embryo transfer of the morphologically best embryo on day 5/6, vitrification of supernumerary embryos and embryo transfer in cumulative frozen-thawed embryo transfer cycles if not pregnant from the fresh cycle.
Study: NCT00565630

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vigamox delivered via the device in spray form
Description: Vigamox delivered 4 times, 1 hour prior to cataract surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vigamox delivered via the device in spray form
Description: Vigamox delivered 4 times, 1 hour prior to cataract surgery
Study: NCT00023322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alpha-2a
Description: Treatment
Study: NCT02490852

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigational infant formula
Description: fed ad libitum

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Commercially available Infant formula
Description: fed ad libitum

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Human milk
Description: fed ad libitum
Study: NCT00110305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC278 25 mg
Description: TMC278 25 mg tablet will be administered once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC278 75 mg
Description: TMC278 75 mg (1 X 25 mg + 1 X 50 mg) tablets will be administered once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC278 150 mg
Description: TMC278 150 mg (1 X 50 mg + 1 X 100 mg) tablets will be administered once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: Efavirenz 600 mg (1 x 600 mg tablet or 3 x 200 mg capsules, depending on formulation locally available) will be administered once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-nucleoside reverse transcriptase inhibitor (NRTIs)
Description: Investigator selected 2 NRTIs: (1) Zidovudine and lamivudine (Combivir) and (2) tenofovir disoproxil fumarate and emtricitabine (Truvada) will be administered as per the package inserts, along with the TMC278 during the study period.
Study: NCT00509561

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy